WO2008069970A3 - Nicotine formulations, kits and systems and methods for their use - Google Patents

Nicotine formulations, kits and systems and methods for their use Download PDF

Info

Publication number
WO2008069970A3
WO2008069970A3 PCT/US2007/024636 US2007024636W WO2008069970A3 WO 2008069970 A3 WO2008069970 A3 WO 2008069970A3 US 2007024636 W US2007024636 W US 2007024636W WO 2008069970 A3 WO2008069970 A3 WO 2008069970A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nicotine
kits
systems
formulations
Prior art date
Application number
PCT/US2007/024636
Other languages
French (fr)
Other versions
WO2008069970A2 (en
Inventor
Igor Gonda
Original Assignee
Aradigm Corp
Igor Gonda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/932,402 external-priority patent/US20080138294A1/en
Priority claimed from US11/932,437 external-priority patent/US8256433B2/en
Priority claimed from US11/931,867 external-priority patent/US20080138398A1/en
Priority claimed from US11/931,921 external-priority patent/US20080138399A1/en
Application filed by Aradigm Corp, Igor Gonda filed Critical Aradigm Corp
Priority to EP07867591A priority Critical patent/EP2086317A4/en
Publication of WO2008069970A2 publication Critical patent/WO2008069970A2/en
Publication of WO2008069970A3 publication Critical patent/WO2008069970A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

This invention relates generally to formulations, compositions, aerosols and kits used to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament and dosage forms thereof formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use.
PCT/US2007/024636 2006-12-01 2007-11-30 Nicotine formulations, kits and systems and methods for their use WO2008069970A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07867591A EP2086317A4 (en) 2006-12-01 2007-11-30 Nicotine formulations, kits and systems and methods for their use

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US86823806P 2006-12-01 2006-12-01
US60/868,238 2006-12-01
US91104407P 2007-04-10 2007-04-10
US60/911,044 2007-04-10
US91318507P 2007-04-20 2007-04-20
US60/913,185 2007-04-20
US91651007P 2007-05-07 2007-05-07
US60/916,510 2007-05-07
US91719007P 2007-05-10 2007-05-10
US60/917,190 2007-05-10
US98207007P 2007-10-23 2007-10-23
US60/982,070 2007-10-23
US11/932,437 2007-10-31
US11/932,402 2007-10-31
US11/932,402 US20080138294A1 (en) 1999-07-16 2007-10-31 Systems and methods for effecting cessation of tobacco use
US11/931,921 2007-10-31
US11/932,437 US8256433B2 (en) 1999-07-16 2007-10-31 Systems and methods for effecting cessation of tobacco use
US11/931,867 US20080138398A1 (en) 1999-07-16 2007-10-31 Dual release nicotine formulations, and systems and methods for their use
US11/931,921 US20080138399A1 (en) 1999-07-16 2007-10-31 Dual release nicotine formulations, and systems and methods for their use
US11/931,867 2007-10-31

Publications (2)

Publication Number Publication Date
WO2008069970A2 WO2008069970A2 (en) 2008-06-12
WO2008069970A3 true WO2008069970A3 (en) 2008-10-16

Family

ID=39492806

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/024641 WO2008069972A2 (en) 2006-12-01 2007-11-30 Systems for effecting cessation of tobacco use
PCT/US2007/024636 WO2008069970A2 (en) 2006-12-01 2007-11-30 Nicotine formulations, kits and systems and methods for their use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2007/024641 WO2008069972A2 (en) 2006-12-01 2007-11-30 Systems for effecting cessation of tobacco use

Country Status (2)

Country Link
EP (2) EP2086527A4 (en)
WO (2) WO2008069972A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EA201100896A1 (en) * 2009-02-11 2012-01-30 ХЕГЛУНД а.с. COMPOSITION INTENDED FOR SUCKING NICOTINE FROM THE FATAL CAVITY WITH THE PURPOSE TO STOP SMOKING
WO2011023796A1 (en) * 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
TWI484958B (en) * 2011-05-19 2015-05-21 Heglund A S A composition for buccal absorption of nicotine for the purpose of smoking cessation
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
RU2541312C2 (en) * 2011-08-31 2015-02-10 Александр Васильевич Иващенко Pharmaceutical composition, method for preparing and device for using it
US10556011B2 (en) 2011-12-02 2020-02-11 Joshua D. Levine Method and system for adding sensory conditioning cues in a pharmacotherapeutic regimen
US10034988B2 (en) 2012-11-28 2018-07-31 Fontem Holdings I B.V. Methods and devices for compound delivery
US10194693B2 (en) 2013-09-20 2019-02-05 Fontem Holdings 1 B.V. Aerosol generating device
JP2018511355A (en) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Drug delivery method and system
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US20170071248A1 (en) 2015-09-16 2017-03-16 Sansa Corporation (Barbados) Inc. System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
JP2020503950A (en) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Device and method for transdermal drug delivery
CA3048677A1 (en) * 2017-03-07 2018-09-13 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
GB201817863D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024097A (en) * 1992-02-20 2000-02-15 J Mom Trust Product for assisting a smoker in giving up the habit
JP3661131B2 (en) * 1992-02-20 2005-06-15 アスペン ファーマケア ヨーロッパ リミテッド Smoking suppression device
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
US6799576B2 (en) * 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
JP4999245B2 (en) * 1999-07-16 2012-08-15 アラディグム コーポレイション System for achieving quit smoking
US20070100000A1 (en) * 2000-11-01 2007-05-03 Epstein Mel H Methods of providing neuroprotection
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2086317A4 *

Also Published As

Publication number Publication date
WO2008069972A2 (en) 2008-06-12
EP2086527A2 (en) 2009-08-12
WO2008069970A2 (en) 2008-06-12
EP2086527A4 (en) 2010-03-03
EP2086317A4 (en) 2010-03-03
EP2086317A2 (en) 2009-08-12
WO2008069972A3 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
WO2008069970A3 (en) Nicotine formulations, kits and systems and methods for their use
WO2008069921A3 (en) Oral transmucosal nicotine dosage form
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2008073942A3 (en) Pharmaceutical compositions and their methods of use
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2009079641A3 (en) Aerosol devices and methods for inhaling a substance and uses thereof
WO2008036791A3 (en) Respirators for delivering clean air to an individual user
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
ME01400B (en) Novel azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
MX2009012484A (en) Coated oral nicotine formulation buffered with amino acid.
WO2007091267A3 (en) Pulmonary delivery of alpha-i proteinase inhibitor
MY177136A (en) Tobacco-based nicotine aerosol generation system
IL220480A0 (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors , preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2006032342A3 (en) Carbonyl compound-containing drug and the use thereof
WO2007061828A3 (en) Pharmaceutical compositions comprising buprenorphine
WO2009141321A3 (en) Tablettable chewing gums comprising nicotine and a buffering agent
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
WO2007137204A3 (en) Methods for the delivery of a beta2 agonist to induce bronchodilation and formulations for use in the same
IL210688A0 (en) Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors
WO2008098180A3 (en) Complementary personal lubrificant compositions and delivery system
AP2150A (en) Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication.
WO2006076097A3 (en) Stable non-crystalline formulation comprising losartan
WO2005110421A3 (en) Aerosol formulation for inhalation of beta agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867591

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007867591

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE